Docket Number:
FDA-1998-D-0067
Issued by:

Guidance Issuing Office

Center for Biologics Evaluation and Research

The purpose of this document is to provide guidance on labeling requirements in the US for blood and blood components.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-1998-D-0067.

Questions?